3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Abstract

Description

Keywords

Breast neoplasms, Breast neoplasms, male, Female, Humans, Male, Observational studies as topic, Randomized controlled trials as topic, Anthracycline, Antineoplastic metal complex, Bevacizumab, Capecitabine, Epidermal growth factor receptor 2, Eribulin, Estradiol, Estrogen receptor, Everolimus, Fulvestrant, Gemcitabine, Lapatinib, Megestrol acetate, Palbociclib, Pertuzumab, Tamoxifen, Taxane derivative, Tumor marker, Vinorelbine tartrate, Article, Bone metastasis, Brain metastasis, Breast cancer, Cancer chemotherapy, Cancer grading, Cancer patient, Cancer radiotherapy, Cancer screening, Cancer survival, Disease free survival, Human, Liver metastasis, Malignant pleura effusion, Mastectomy, Next generation sequencing, Overall survival, Palliative therapy, Patient preference, Phase 2 clinical trial (topic), Phase 3 clinical trial (topic), Practice guideline, Progression free survival, Randomized controlled trial (topic), Tumor ablation, Breast tumor, Observational study, Pathology

Citation

Endorsement

Review

Supplemented By

Referenced By